Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

OS Therapies Incorporated Common Stock (NY: OSTX )

2.230 +0.240 (+12.06%)
Official Closing Price Updated: 8:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about OS Therapies Incorporated Common Stock

< Previous 1 2 Next >
Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer
OS Therapies advances OST-HER2, a HER2-targeted immunotherapy, with plans for FDA submission following promising Phase 2b data in osteosarcoma. 
Via Benzinga
Exposures Product Safety
Friday's session: gap up and gap down stocks
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Top movers in Friday's pre-market session
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
From OS Therapies, Inc.
Via Business Wire
OS Therapies Provides Corporate Update
From OS Therapies, Inc.
Via Business Wire
RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis
Via ACCESS Newswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
From OS Therapies
Via Business Wire
Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why
Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves. 
Via Stocktwits
Exposures Product Safety
Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?
OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls. 
Via Benzinga
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
From OS Therapies, Inc.
Via Business Wire
OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference
From OS Therapies, Inc.
Via Business Wire
OS Therapies Announces Closing of $6 Million Private Placement
From OS Therapies, Inc.
Via Business Wire
OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online
From OS Therapies, Inc.
Via Business Wire
OS Therapies Announces Pricing of $6 Million Private Placement
From OS Therapies, Inc.
Via Business Wire
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
From OS Therapies, Inc.
Via Business Wire
OS Therapies to Present at The Spartan Capital Investor Conference
From OS Therapies
Via Business Wire
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
From OS Therapies
Via Business Wire
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
From OS Therapies
Via Business Wire
OS Therapies to Present at the LD Micro Main Event XVII
From OS Therapies
Via Business Wire
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
From OS Therapies
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
From OS Therapies
Via Business Wire
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
From OS Therapies
Via Business Wire
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector 
Via News Direct
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (OSTX, ATNM, CRBP, PBYI)
Via AB Newswire
Transforming Oncology: Stocks to Watch in the Oncology Sector
Transforming Oncology: Stocks to Watch in the Oncology Sector 
Via News Direct
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Via ACCESSWIRE
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
From OS Therapies
Via Business Wire
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
From OS Therapies
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.